Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.

10 In contrast, a nationwide population-based study of 1719 biologics-naïve patients with UC in Denmark demonstrated that the risks of surgery and new corticosteroid initiation were comparable among IFX users and ADA users; however, ADA was associated with a higher risk of all-cause hospitalization and serious infections, and showed a trend toward a higher risk of UC-related hospitalization, compared with IFX. 11 Although the results of these two studies are not identical, these results may suggest that IFX may be more beneficial than ADA in the treatment of UC.

also in 53,322 other papers